Immupharma PLC Result of AGM (4745Q)

TIDMIMM

RNS Number : 4745Q

Immupharma PLC

28 June 2022

RNS: RELEASE 28 June 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

2022 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

ImmuPharma's Chairman & CEO, Tim McCarthy said: "We are delighted to have had such overwhelming support from right across our shareholder base. This includes corporate, institutional and long-term private shareholders, in respect to all of the AGM resolutions. The support for the re-appointment of the new Board, an integral part of the management restructuring, successfully completed in August last year, being part of the resolutions being approved.

Importantly, we also announced yesterday, a key progress update on our lead programme, Lupuzor(TM). Our partner, Avion Pharmaceuticals, who is also a major supportive shareholder, has confirmed that having met all the Food and Drug Administration's ("FDA") requirements, they have sought final guidance from the FDA, as they actively prepare for the start of the international Phase 3 trial of Lupuzor(TM) in Lupus patients. This is a key inflection point for the positive progress of Lupuzor(TM) towards becoming a first line therapy to many Lupus sufferers globally.

On behalf of the new Board, I would like to thank all our shareholders and collaborators for their continued belief in ImmuPharma."

 
            Resolution                 For       % For   Against   % Against   Withheld 
 1. To receive the accounts 
  of the Company for the 
  year ended 31 December 
  2021 together with the 
  reports thereon of the 
  directors and auditors 
  of the Company                    53,394,853   99.14   463,666     0.86      837,178 
                                   -----------  ------  --------  ----------  --------- 
 2. To re-appoint Tim McCarthy 
  as a director of the Company      53,310,582   98.99   542,318     1.01      842,797 
                                   -----------  ------  --------  ----------  --------- 
 3. To re-appoint Dr Tim 
  Franklin as a director 
  of the Company                    53,300,349   99.00   540,213     1.00      855,135 
                                   -----------  ------  --------  ----------  --------- 
 4. To re-appoint Dr Sanjeev 
  Pandya as a director of 
  the Company                       53,304,688   99.00   535,874     1.00      855,135 
                                   -----------  ------  --------  ----------  --------- 
 5. To re-appoint Lisa 
  Baderoon as a director 
  of the Company                    53,304,363   99.00   536,199     1.00      855,135 
                                   -----------  ------  --------  ----------  --------- 
 6. To re-appoint Nexia 
  Smith & Williams as auditors 
  of the Company                    53,280,466   99.02   527,057     0.98      888,174 
                                   -----------  ------  --------  ----------  --------- 
 7. That subject to the 
  passing of resolution 
  10, each ordinary share 
  of GBP0.10 in the capital 
  of the Company be sub-divided 
  into one ordinary share 
  of GBP0.01 each and one 
  deferred share of GBP0.09 
  each                              53,000,307   98.47   821,831     1.53      873,559 
                                   -----------  ------  --------  ----------  --------- 
 8. That the Directors 
  be authorised for the 
  purpose of Section 551 
  of the Companies Act 2006 
  (the "Act") to allot shares 
  on the basis as set out 
  in the Notice of Meeting. 
  Special Resolution                52,999,192   98.58   765,320     1.42      931,185 
                                   -----------  ------  --------  ----------  --------- 
 9. That, subject to the 
  passing of Resolution 
  8, the Directors are hereby 
  empowered pursuant to 
  section 571 of the Act 
  to allot equity securities 
  on the basis as set out 
  in the Notice of Meeting          52,972,066   98.53   792,446     1.47      931,185 
                                   -----------  ------  --------  ----------  --------- 
 10. That, subject to the 
  passing of resolution 
  7, the articles of association 
  of the Company be amended 
  as set out in the Notice 
  of Meeting                        52,992,957   98.56   772,458     1.44      930,282 
                                   -----------  ------  --------  ----------  --------- 
 

As at the date of the AGM, the number of issued ordinary shares of the Company was 284,984,933 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman and Chief Executive 
    Officer                                       [phone] 
   Lisa Baderoon, Head of Investor Relations 
    & Non-Executive Director                      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                  [phone] 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes, Bob Pountney     [phone] 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   [phone] 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor(TM), within our P140 platform, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of Lupus, a debilitating and potentially life threatening auto immune disease. Preclinical analysis suggests therapeutic activity for many other autoimmune diseases targeted through our P140 platform, that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDZGZVGRMGZZM

(END) Dow Jones Newswires

June 28, 2022 06:42 ET (10:42 GMT)